TCGA has grouped glioblastomas relying on proteomic data into three classes: one showing epidermal growth factor receptor (EGFR) mutations or amplifications, the second having ligand-driven platelet-derived growth factor (PDGF) activation, and the third with a loss of RAS regulator, NF1 [41]. The gene discussed is EGFR; the disease is glioblastoma.